Today’s AI Top Pick: ALNY
9/15/2026 · Reliable Bullish screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live ALNY price forecast →
Alnylam is the cleanest setup in the pool right now: bullish_prob = 1, near_term_bullish = 1, and the tape is showing a reversal signature — not a chase. On the 4h timeframe, price sits at just 3.45% of the 21-bar range with a -24.44% drawdown from the high, yet the model is forecasting +59.34% short / +55.77% mid / +62.83% long. That is the textbook 'washed-out, model sees mean reversion' profile the screen was built to catch. The daily confirms with fc_mid +40.89% and fc_long +27.91%, and the daily is already turning (recent_21bar +11.30%, pos 59.32%) — momentum is inflecting off the low without being extended. Fundamentals reinforce the tape rather than fight it. PEG 0.33 (best in the pool), ROE 100.7%, salesYoY +95.14%, epsNextY +50.99%, profit margin 16.82% on 79.65% gross, recom 1.62 with targetUpsidePct 49.7%. FwdPe 24.81 is reasonable for a biotech growing sales near triple digits, and institutional ownership is essentially maxed (100.73%) — the -37.13% YTD / -46.34% 1yr drawdown is a de-rating in a fundamentally accelerating business, not a broken story. News flow is supportive: today's Yahoo piece is explicitly titled 'Alnylam's Sell-Off Looks Ugly — but Wall Street Still Sees a Much Brighter Picture,' plus a Morgan Stanley healthcare conference appearance and inclusion in the oligonucleotide market outlook. No dilution, no legal issue, no guidance cut. Contrast with ORCL, which has bullish_prob 1 but is being actively questioned on balance-sheet strain from the AI buildout (Yahoo) and is slipping premarket — I am passing on ORCL as #1 specifically because the headline undercuts an already-mixed weekly forecast (-3.86% fc_long on 1wk). Why today: 4h dd of -24% with pos_in_range of 3.45% means you are buying near the lower bound of the recent bar, not chasing the top. The 1h isn't shown, but 4h fc_short of +59% suggests the model expects the bounce to begin immediately — waiting risks missing the initial impulse leg. This is the highest-conviction combination of deep-oversold entry + monster forecast magnitude + clean fundamentals + supportive news in the entire list.
- Weekly tape is still soft (recent_21bar_pct -15.58%, fc_short -0.11%) — if the daily bounce fails, the higher-TF downtrend reasserts
- Biotech single-name headline risk: pipeline/trial news can cause 10–20% single-day moves regardless of setup
- -37% YTD / -46% 1yr means overhead supply from trapped longs at every rally into $270–$290
- FwdPe 24.81 and PS 6.96 leave zero cushion if salesYoY (currently +95%) decelerates on next print
- Debt/Equity 2.21 is elevated for a biotech; any rate-driven risk-off hits leverage names harder
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | ALNY | BUY NOW | 9.1 | Washed-out 4h (pos 3.45%, dd -24%) with fc +59/+56/+63% and best-in-pool PEG 0.33; supportive news. |
| 2 | CLBT | BUY NOW | 8.3 | Multi-TF alignment 1h/4h/1d with recom 1.0 and near_term_bullish 1.0; weekly is the only blemish. |
| 3 | MIR | BUY NOW | 7.8 | Bottom-of-range on 4h (pos 0%) with +56%/+41%/+63% forecasts and insider buying + Jefferies Buy. |
| 4 | FUTU | BUY PULLBACK | 7.5 | Fundamentals stellar (PE 10.98, ROE 30.94%, margin 42.92%) but 4h pos 94% — chasing here; wait for pullback to $102–$105. |
| 5 | TIGR | BUY PULLBACK | 7.3 | Forecasts massive (+75/+79/+88% on 4h) and PE 8.19, but 4h pos 88% and weekly dd -28% — micro-cap volatility risk. |
| 6 | VERX | BUY PULLBACK | 6.8 | Daily fc_long +54.82% and near_term 0.6, but PE 608 and profit margin 0.45% make this a pure momentum trade. |
| 7 | ETOR | BUY NOW | 6.7 | Deep 4h dd -27%, pos 2.22% with fc +19/+32/+40%; fundamentals clean (D/E 0.03, margin 26.96%) but bullish_prob null. |
| 8 | TMUS | BUY NOW | 6.5 | Cleanest large-cap: bullish_prob 1, 1d fc_long +13.81%, mid-range entry, but forecast magnitudes modest. |
| 9 | FIGR | BUY PULLBACK | 6.3 | Positive news catalysts (BofA, Figure Connect) but 4h pos 98.79% and PS 13.09 — no margin of safety at entry. |
| 10 | ORCL | WAIT | 6.0 | 1d fc_mid +24.66% is real, but AI-buildout balance-sheet headline and premarket slip cap conviction; 1wk fc_long -3.86%. |
| 11 | DOX | BUY PULLBACK | 5.9 | Every TF green including weekly (+24.15% fc_long) but pos 93–98% on all TFs — chasing at highs. |
| 12 | KKR | WAIT | 5.7 | Bullish_prob 1 but near_term only 0.2, 1h pos 100%, and 1d fc_short -3%; better entries coming. |
| 13 | WAY | AVOID | 5.2 | Bullish_prob 0.2 and short-term forecasts negative (1d fc_short -10.23%) despite 4h pos 100%; extended. |
| 14 | SE | WAIT | 4.9 | Mixed signals: 1wk fc_long +27.91% but 4h fc_mid -2.86% and 1d fc_short -3.14%; PEG 1.17 offers no discount. |
| 15 | DEFT | AVOID | 4.5 | Nasdaq delisting review headline is a hard veto regardless of forecast; sub-$1 price adds tail risk. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord